Use of an antibody that binds to an activation inducible lymphocyte immunomodulatory molecule (ailim) in the manufacture of a pharmaceutical composition for suppressing, treating or preventing an inflammatory bowel disease

摘要

Antibodies against AILIM (also called ICOS and 8F4). were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases.